ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 59 filers reported holding ACLARIS THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $154,000 | +4.8% | 59,766 | -34.1% | 1.69% | +357.7% |
| Q2 2020 | $147,000 | +44.1% | 90,686 | -7.7% | 0.37% | +49.4% |
| Q1 2020 | $102,000 | -53.0% | 98,286 | -14.6% | 0.25% | +35.7% |
| Q4 2019 | $217,000 | +33.1% | 115,036 | -23.6% | 0.18% | +48.0% |
| Q3 2019 | $163,000 | +41.7% | 150,636 | +185.8% | 0.12% | +73.2% |
| Q2 2019 | $115,000 | – | 52,700 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |